1111P

New prognostic frontiers for lung neuroendocrine tumors: an Italian-Spanish multicentric study of 200 cases.

Anna La Salvia¹, Irene Persano², Monica Verrico³, Massimiliano Bassi⁴, Roberta Modica⁵, Alessandro Audisio², Giulia Puliani⁶, Maria Rinzivillo⁷, Isabella Zanata⁸, Roberto Baldelli⁹, Paola Razzore¹⁰, Francesco Panzuto⁷, Marco Volante¹¹, Elisa Giannetta¹², Marialuisa Appetecchia⁶, Maria Chiara Zatelli⁸, Annamaria Colao⁵, Maria Pia Brizzi², Rocio Garcia-Carbonero¹, Antonqiulio Faqqiano¹³.

1 Medical Oncology Department, University Hospital 12 De Octubre, Madrid, Spain, 2 Department of Oncology, San Luigi Gorzaga University Hospital, Orbassano, Italy, 3 Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Italy, 4 Department of Clinical Medicine and Surgery, Dictinicolourbent of Laging Eneral National Cancer Institute IRCCS, Rome, Italy, 7 Digestive Disease Unit, EMETS Center of Excellence, Sant Andrea University Hospital, Rome, Italy, 8 Department of Medicine, University of Rome, Italy, 8 Department of Medical Specialities, A.O. San Carilloid, 18 Department of Medicine, University of Perara, Italy, 9 Endocrinology Unit, Department of Oncology, Pathology Unit, 18 Department of Medicine, University of San Luigi Hospital, U

Background

Well-differentiated neuroendocrine tumors of the lung (Lung NET) are classified as typical (TC) and atypical(AC) carcinoids, on the basis of mitotic count and presence of necrosis. However, the identification ofprognostic factors, other than TNM stage and histopathological diagnosis of AC versus TC, are still lacking.

Methods

We assessed the association of clinical and pathological data with survival in a multicenter retrospective series of 200 surgically resected lung NET from 8 Italian&1 Spanish Institutions. Patients data were collected and analyzed by SPSS program.

Conclusions

This study confirms the prognostic relevance of TNM stage and of the diagnosis of AC, to stratify NET patients. Additionally, our analysis suggests a potential prognostic value for new clinical and pathological features, asmale gender, left-sided primary tumor and high proliferation index.

Contact: alasalvi@ucm.es A. La Salvia has no conflicts of interest to declare.

Results

Feature	N (=200)	%
Gender Male	80	60.0
Female	120	40.0
Age Median (range)	60 (13-86)	
Side		
Left	81	40.5
Right	119	59.5
Stage		
! 	113 56	56.5 28,0
III	17	8.5
IV Unknown	12 2	6.0 1.0
Nodal status N0	141	70.5
N+	50	25.0
Unknown	9	4.5
Diagnosis		
TC AC	138 62	69.0
AL	62	31.0
Ki67 1-2%	87	43.5
3-19%	74	43.5 37.0
≥20%	8	4.0
Unknown	31	15.5
Mitotic count		
< 2 per 10 HPF ≥ 2 per 10 HPF	108 64	54.0 32.0
Unkonwn	28	14.0
Necrosis		
No	164	82.0
Yes Unkonwn	35 1	17.5 0.5
Ulikuliwii	'	0.5
PFS months	36 (0.5-323)	
(range)		
OS months	49 (0.6-323)	
(range)	()	

Table 1. Characteristics of the study population




Figure 1 Kaplan Meier OS.

Feature		HR	95% CI
Gender Male vs female	0.0127	2.913	0.920-9.222
Tumor location Right vs left parenchyma	0.0669	2.597	0.967-6.977
TNM stage III-IV vs I-II	0.0208	11.252	2.235-56.653

Table 2. Multivariate analysis OS